Workingdogs Logo
Working Dogs Outfitter Training Books & Videos Free Trainer Directory
Tactical & Outdoor Gear Online Brand New All Pet Store New Articles
Brand new hot deals! Breed Calendars & Misc. Gifts Working Dog Forum
Updated New Book Titles! Veterinary Library Free User Blogs
The international magazine for and about working and sporting dogs -- and the people who love them.
 
Working Dog Ads Free Working Dog Blog Working Dog Forums Working Dog Events New Working Dog Articles



Facebook

Twitter




Add Working Dogs
Headlines to your Site

Click Here for Details

Subscribe to the
Working Dogs Newsletter
EnterYour e-mail address


Pro Training Shop

The Dog Shop

Tactical and Outdoor Gear Online

Veterinary Library

Brand New All Pet Store

Breed Calendars and Misc. Gifts

Updated New Book Titles!

Our Horse Gear

Dog First Aid

Australian Cattle Dogs

Australian Shepherds

Belgian Malinois

Bernese Mountain Dogs

Border Collies

Bouvier des Flandres

Bulldogs

Cane Corso

Doberman Pinschers

German Shepherd Dogs

Hound Dogs

Labrador Retrievers

Mastiffs

Newfoundlands

Pit Bulls

Rottweilers

Swiss Mountain Dog

K9 Kondo
{short description of image}
Search Amazon:

Enter Keyword:

Canine Trauma



Outsmarting the Saboteur

If the body is like a well-defended nation,
then immune mediated hemolytic anemia is a clever saboteur
who has caused a revolt within the country’s army.

No one understands why this immune disorder causes the body's antibodies to mark its own red blood cells for destruction. In severe cases, the lack of circulating red blood cells eventually causes the body to become oxygen-starved - leading to tissue destruction and organ failure.

Blood transfusions, along with heavy doses of corticosteroids and other immunosuppressive agents, have proven to be effective therapy for humans affected by IMHA. But in dogs, it's a different story: their chances of surviving this immune disorder are only about 40 per cent.

Dr. Anthony Carr, an internal medicine specialist at the Western College of Veterinary Medicine (WCVM), is one of the many scientists across North America who has tried to improve the odds for dogs suffering from this disease. Carr began investigating IMHA when he was a resident at the University of Wisconsin in the early 1990s, and his work has continued at WCVM where clinicians see about 30 cases of canine IMHA every year.

"The sad thing is that nothing has changed since 1994. Some new studies come out, but we still lose just as many dogs."

The problem, in Carr's opinion, is that most studies have focused on important but less crucial issues such as outcome, the disease's risk factors and the potential use of new immunosuppressant drugs.

One of those studies was conducted at WCVM in 2001 when Dr. Astrid Nielssen teamed up with Drs. Carr, Susan Taylor and Marion Jackson. With financial support from the Companion Animal Health Fund, the small study evaluated the use of cyclosporine (a drug often used during human transplants) in combination with two corticosteroids: prednisone and azathioprine.

Since the study only included 12 dogs, Carr says more research needs to be done before scientists determine if the combination of drugs has potential for long-term IMHA therapy. Another limiting factor: more than half of the dogs involved in the study died soon after beginning treatment for the disease- an outcome that mirrors the reality at veterinary clinics across Canada and the U.S.

"Most IMHA dogs die within the first three or four days, and that's why I think we're trying to answer the wrong question," points out Carr. "Instead of finding the best immunosuppressant therapy, we should figure out a way to stop them from dying on us before the corticosteroids and immunosuppressive drugs even get a chance to work."

What causes most of these dogs to die? Thromboembolism - or small blood clots - is the main killer of dogs diagnosed with IMHA, says Carr, who published an IMHA study with Drs. David Panciera and Linda Kidd in the Journal of Veterinary Internal Medicine in 2002. Searching for the disease's trends, Carr and his former University of Wisconsin colleagues reviewed 72 cases of canine IMHA. The study had a 58 per cent mortality rate, and of those dogs that died, 80 per cent had blood clots present in their bodies at necropsy. 

 To address the issue of blood clots, several WCVM scientists have been exploring the use of heparin - a naturally occurring compound with anti-thrombotic and anticoagulant effects. This biological product is used to treat conditions like deep vein thrombosis in humans, and veterinarians also give IMHA-affected dogs regular injections of heparin to prevent clot development.

Even so, Carr says scientists don't entirely understand the drug's effect on humans - and they know even less about its effect on dogs: "The response is inconsistent from one dog to another, and even in the same animal, you can get an entirely different response from the next injection."

The variability in injectable heparin dosing, combined with the inconvenience of giving dogs repeated injections, led Carr and graduate student Dr. Mala Sivasankar to develop a CAHF-supported pilot project that tested the potential of using oral heparin in dogs. Their co-investigator was Dr. Linda Hiebert, a WCVM scientist who has used rat models to show that oral heparin is rapidly absorbed and effectively reduces the formation of blood clots without increasing the chances of internal bleeding.

While more work is necessary before scientists can accurately gauge oral heparin's anti-thrombotic value, none of the dogs involved in the pilot study showed any evidence of bleeding. Those initial results correlate with Hiebert's previous findings, plus they give Carr hope that oral heparin may emerge as an effective tool in the battle against this self-sabotaging disease.

But for the long term, Carr says it's crucial for scientists to discover why IMHA causes dogs to clot. Once that mystery is solved, clinicians will be closer to the goals of developing effective therapies and more consistent management practices that will save dogs in those first crucial days.

"Blood clotting is a very rare complication in humans with IMHA. But all dogs with IMHA develop blood clots even though they're a species that rarely suffers from thromboembolism. So what's so special about this disease that it makes dogs do something they usually don't?" questions Carr. "That's what we need to answer before we can truly manage this disease."

Reprinted with permission of Vet Topics, publication for the Western College of Veterinary Medicine's Companion Animal Health Fund.
For more information, visit www.cahf.usask.ca




HOME | SEARCH | BOOK & Gear | Classifieds | Articles | Health | Resources | About Us | Privacy Statement
All site contents and design Copyright 1996 © Working Dogs
Please feel free to link from your site to any of the pages on Working Dogs domain in a non-frame presentation only.
You may not copy, reproduce, or distribute any site content in any form.
Copying and distribution of any Working Dogs domain content may be done only with publisher's consent.
For information on reprinting articles please contact Working Dogs.
Page